---
title: "CAPR Capricor Therapeutics"
author: "Akshay Gulabrao"
date : "2025 October 27"
bibliography: library.bib
link-citations: true
---

[Home](./index.html)

---

Capricor Therapeutics (CAPR) has a drug named Deramiocel (CAP-1002) to treat Duchenne muscular dystrophy. It's currently in Phase 3 and they are due to release data in a few weeks.

Martin doesn't think the drug works.

Duchenne Muscular Dystrophy is a severe X-linked recessive disorder caused by mutations in the DMD gene, which encodes a structural cytoskeletal protein in muscle cells named **dystrophin**. 

There are currently a few drugs approved to treat DMD.
- Elevidys: distributes a gene to make dystrophin-like protein throughout muscles
- Emflaza: does not fix dystrophin mutation, but slows the decline in muscle strength by decreasing IL-1,IL-6, and TNF‑α
- Agamree: slows decline in motor and respiratory function. same result as emflaza, but different moA
- Duvyzat: inhibits HDAC enzymes


# Elevidys

## Primary Endpoint

[Elevidys Clinical Trial Paper](https://jamanetwork.com/journals/jamaneurology/fullarticle/2767086)
[Elevidys Clinical Trial Paper 2](https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.26755)


The primary outcome measure was Number of Participants with Adverse Events (AEs). They used 4 people in the study and reported no adverse events. 

## Secondary Endpoint

The change in delandistrogene moxeparvovec dystrophin using western blot, immunofluorescense, and IF PDPF and the 100-meter timed test.

By western blot, 
